Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,595,848 shares of the company's stock after purchasing an additional 129,601 shares during the period. Vanguard Group Inc. owned about 5.26% of Replimune Group worth $43,546,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sei Investments Co. purchased a new position in Replimune Group in the fourth quarter valued at $148,000. KLP Kapitalforvaltning AS purchased a new position in shares of Replimune Group in the 4th quarter valued at about $150,000. Arizona State Retirement System purchased a new position in shares of Replimune Group in the 4th quarter valued at about $156,000. BNP Paribas Financial Markets grew its position in shares of Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock worth $165,000 after buying an additional 6,748 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Replimune Group during the fourth quarter worth approximately $189,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REPL has been the topic of a number of analyst reports. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets upped their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $19.43.

Remove Ads

Replimune Group Trading Up 2.7 %

NASDAQ:REPL traded up $0.20 on Tuesday, reaching $7.71. The stock had a trading volume of 1,102,761 shares, compared to its average volume of 868,627. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a market cap of $593.79 million, a price-to-earnings ratio of -2.51 and a beta of 1.26. The firm's fifty day moving average is $11.21 and its two-hundred day moving average is $11.86. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Equities analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.